PSA
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- PSA is a prostate health marker, not a cancer test. Elevated PSA can reflect benign conditions including BPH and prostatitis. Conversely, up to 15% of men with PSA below 4.0 ng/mL can have prostate cancer on biopsy. Context and trend matter more than a single value.
- PSA velocity is more informative than a single reading. A rise of 0.75 ng/mL or more per year — even within the 'normal' range — is a meaningful signal that warrants evaluation. This is why establishing a baseline in your 40s and tracking over time is the highest-value approach.
- Age-adjusted thresholds matter. A PSA of 3.5 ng/mL is more concerning in a 45-year-old than in a 70-year-old. Younger men have smaller prostates and naturally lower PSA, so the traditional 4.0 ng/mL cutoff is too lenient for men under 60.
- Free PSA percentage improves specificity. When total PSA is in a borderline range (2–10 ng/mL), measuring free PSA can help distinguish benign from malignant causes. A free PSA above 25% of total PSA suggests benign disease; below 10% raises concern for cancer.
- Several factors can transiently raise PSA. Ejaculation within 24–48 hours, vigorous cycling, prostate biopsy, and acute prostatitis can all elevate PSA. Avoid these factors before testing to avoid false elevations.
PSA: The Most Important Prostate Test — and the Most Misunderstood
PSA screening has been at the center of one of medicine's most contentious debates for the past three decades. Early widespread screening in the 1990s led to significant overdiagnosis — the detection and treatment of slow-growing cancers that would never have caused harm — alongside real benefits in catching aggressive cancers early. The pendulum swung toward discouraging routine screening, creating a generation of men who were never tested.
The current consensus is more nuanced: PSA is a valuable tool when used intelligently — with age-appropriate thresholds, serial testing to assess velocity, and a staged approach to elevated values that includes MRI before reflexive biopsy. Used this way, PSA monitoring provides meaningful, actionable information about prostate health.
For men focused on longevity, the most important shift in thinking is from single-value screening to longitudinal tracking. Establishing a baseline PSA in your 40s and measuring it every 1–2 years generates a trend line that is far more informative than any isolated reading. A PSA that rises from 1.2 to 2.8 ng/mL over three years — even though both values are technically "normal" — conveys meaningful information that should prompt evaluation.
Understanding Your PSA Number
PSA levels must be interpreted in context — absolute value, age, prostate volume, trend, and free PSA fraction all contribute to a complete picture.
| Age | Reassuring | Monitor | Investigate |
|---|---|---|---|
| 40–49 | < 2.0 ng/mL | 2.0–2.5 ng/mL | > 2.5 ng/mL |
| 50–59 | < 2.5 ng/mL | 2.5–3.5 ng/mL | > 3.5 ng/mL |
| 60–69 | < 3.5 ng/mL | 3.5–4.5 ng/mL | > 4.5 ng/mL |
| 70+ | < 4.0 ng/mL | 4.0–5.5 ng/mL | > 5.5 ng/mL |
These thresholds represent decision points for discussion with a physician — not automatic triggers for biopsy. Equally important is PSA velocity: any rise exceeding 0.75 ng/mL per year warrants evaluation regardless of absolute level.
Already have your lab results? See how your PSA and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →What PSA Is — and Isn't — Measuring
PSA is prostate-specific but not cancer-specific. It is produced by normal prostate epithelial cells as part of the liquefaction of seminal fluid — an entirely normal physiological function. Elevated serum PSA simply means that more PSA than usual is leaking from the prostate into the bloodstream, which can happen for several reasons beyond cancer.
Benign prostatic hyperplasia (BPH) — non-cancerous prostate enlargement that affects most men over 50 — increases PSA proportionally to prostate volume. A man with BPH may have a PSA of 5–6 ng/mL with no malignancy. This is the most common cause of elevated PSA in older men.
Prostatitis — prostate inflammation or infection — can dramatically elevate PSA, sometimes to very high levels. Acute bacterial prostatitis can push PSA above 100 ng/mL temporarily. If PSA is unexpectedly high and symptoms of prostatitis are present (pelvic pain, urinary symptoms, fever), treating prostatitis and retesting is appropriate before proceeding with cancer workup.
Prostate cancer — malignant cells produce PSA at higher concentrations than normal cells and with disrupted architecture that allows more to leak into the bloodstream.
This lack of specificity is why PSA interpretation requires clinical context and why serial testing over time is more valuable than any single measurement.
Free PSA: Improving Specificity
PSA circulates in the blood in two forms: bound to proteins (the majority) and free (unbound). The ratio of free to total PSA — expressed as a percentage — provides additional diagnostic information when total PSA is in the borderline range (roughly 2–10 ng/mL).
Prostate cancer cells produce less free PSA relative to total PSA than benign prostate tissue. Therefore:
- Free PSA above 25%: suggests benign disease (BPH or prostatitis) — lower probability of cancer
- Free PSA 10–25%: intermediate zone — clinical context and other factors determine next steps
- Free PSA below 10%: raises concern for prostate cancer — warrants urological evaluation
Requesting free PSA alongside total PSA when values are borderline is a simple, inexpensive step that can help avoid unnecessary biopsies or identify cases warranting expedited evaluation.
Sources
- Carter HB, et al. "Early Detection of Prostate Cancer: AUA Guideline." Journal of Urology, 2013. PubMed →
- Catalona WJ, et al. "Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer." New England Journal of Medicine, 1991. PubMed →
- Thompson IM, et al. "Prevalence of Prostate Cancer Among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter." New England Journal of Medicine, 2004. PubMed →
| Range Type | Value (ng/mL) | Notes |
|---|---|---|
| Standard Clinical Range | < 4.0 ng/mL (general) · Age-adjusted ranges vary | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 2.5 ng/mL (men under 60) · < 3.5 ng/mL (men 60–70) |
Associated with reduced all-cause mortality and extended healthspan.
Many longevity and urology practitioners use lower thresholds than the traditional 4.0 ng/mL cutoff, particularly for younger men. PSA velocity — the rate of rise over time — is often more clinically important than any single value. A rise of more than 0.75 ng/mL per year warrants investigation regardless of absolute level. Free PSA percentage (free PSA ÷ total PSA) provides additional specificity when total PSA is borderline.
|
Already have your results? See what your PSA and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
At what age should men start testing PSA?
Guidelines vary, but longevity-focused practitioners generally recommend establishing a PSA baseline at age 40–45 for men at average risk, and age 35–40 for men with a first-degree relative with prostate cancer (which doubles risk) or for African American men (who have higher prostate cancer incidence and often more aggressive disease at younger ages). The purpose of early baseline testing is not to screen for current cancer — the probability is low — but to establish a personal reference point against which future values can be compared. PSA velocity calculated from multiple readings over years is far more informative than any single measurement.
What should I do if my PSA is elevated?
A single elevated PSA reading does not require immediate biopsy — this is where guidelines have evolved significantly in recent years. If your PSA is elevated, reasonable next steps include: (1) Repeat the test in 4–6 weeks after eliminating potential confounders (recent ejaculation, vigorous cycling, prostatitis symptoms). (2) Calculate PSA velocity by comparing to prior values if available. (3) Consider free PSA testing to assess the free:total ratio. (4) Discuss with a urologist — multiparametric MRI (mpMRI) of the prostate is increasingly used as an intermediate step before biopsy, with high sensitivity for clinically significant cancer while avoiding unnecessary biopsies for low-grade disease. (5) Consider genetic context — family history, race, and BRCA carrier status all affect the risk interpretation.
Can testosterone therapy affect PSA?
This is a nuanced question with an evolving evidence base. Historically, testosterone therapy was contraindicated in men with a history of prostate cancer, based on the assumption that testosterone 'feeds' prostate cancer. More recent evidence has substantially complicated this picture. In men without known prostate cancer, testosterone therapy causes a modest, short-term rise in PSA in the first 3–6 months that typically plateaus — likely reflecting normalization of prostate function rather than cancer stimulation. Most guidelines now recommend baseline PSA testing before starting testosterone therapy, repeat testing at 3–6 months, and ongoing monitoring. Men considering testosterone therapy should discuss PSA monitoring with their prescribing physician.
What is PSA density and why does it matter?
PSA density adjusts total PSA for prostate volume — calculated by dividing PSA (ng/mL) by prostate volume (measured by ultrasound, in mL). A larger prostate naturally produces more PSA, so the same PSA level is less concerning in a man with a large prostate than in a man with a small one. PSA density above 0.15 ng/mL/mL is associated with higher risk of clinically significant prostate cancer on biopsy, independent of total PSA. It is increasingly used in clinical decision-making to avoid unnecessary biopsies in men with elevated PSA due to large benign prostates.
Does diet affect PSA?
Several dietary factors have demonstrated associations with PSA and prostate cancer risk. High consumption of processed meat and dairy (saturated fat) is associated with elevated PSA. Lycopene (from tomatoes, especially cooked), cruciferous vegetables, green tea, and omega-3 fatty acids have shown inverse associations with PSA and prostate cancer risk in epidemiological studies. Exercise and maintaining a healthy body weight are consistently associated with lower PSA and reduced prostate cancer risk. Obesity is associated with more aggressive prostate cancer in part because adipose tissue converts androgens to estrogens, which have complex effects on prostate cell growth.